ES2096559T3 - Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso. - Google Patents

Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.

Info

Publication number
ES2096559T3
ES2096559T3 ES89307374T ES89307374T ES2096559T3 ES 2096559 T3 ES2096559 T3 ES 2096559T3 ES 89307374 T ES89307374 T ES 89307374T ES 89307374 T ES89307374 T ES 89307374T ES 2096559 T3 ES2096559 T3 ES 2096559T3
Authority
ES
Spain
Prior art keywords
humano
interferon gamma
gamma
huifn
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89307374T
Other languages
English (en)
Inventor
Masashi Kurimoto
Masakazu Mitsuhashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Hayashibara Biochemical Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Hayashibara Biochemical Laboratories Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Application granted granted Critical
Publication of ES2096559T3 publication Critical patent/ES2096559T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN HULFN-(TAU), A UN PROCEDIMIENTO PARA PREPARAR DICHO HULFN-(TAU), Y SU USO (EN ADELANTE ABREVIADO COMO "HULFN-(TAU)"), MAS ESPECIALMENTE, A UN HULFN-(TAU) QUE TIENE UNA ESTRUCTURA NUEVA, A UN PROCEDIMIENTO PARA PREPARAR DICHO HULFN-(TAU), Y A UN AGENTE QUE CONTIENE DICHO HULFN-(TAU) COMO COMPONENTE EFICAZ, QUE ESTA DESTINADO A LA PREVENCION O TRATAMIENTO DE ENFERMEDADES SUSCEPTIBLES A HULFN-(TAU).
ES89307374T 1988-07-23 1989-07-20 Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso. Expired - Lifetime ES2096559T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63184069A JP2969461B2 (ja) 1988-07-23 1988-07-23 ヒトγ−インターフェロンとその製造方法並びに用途

Publications (1)

Publication Number Publication Date
ES2096559T3 true ES2096559T3 (es) 1997-03-16

Family

ID=16146838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89307374T Expired - Lifetime ES2096559T3 (es) 1988-07-23 1989-07-20 Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.

Country Status (8)

Country Link
EP (1) EP0353910B1 (es)
JP (1) JP2969461B2 (es)
KR (1) KR100190555B1 (es)
AT (1) ATE128188T1 (es)
AU (1) AU618382B2 (es)
CA (1) CA1340704C (es)
DE (1) DE68924316T2 (es)
ES (1) ES2096559T3 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05247078A (ja) * 1992-03-03 1993-09-24 Japan Tobacco Inc 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体
EP0721780A3 (en) * 1994-12-16 1997-12-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for promoting platelet and/or leukocyte production
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA3108066A1 (en) * 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU184972B (en) * 1981-12-01 1984-11-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing human gamma interferone
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
ZA844070B (en) * 1983-06-01 1984-12-24 Genentech Inc Gamma interferon-lymphotoxin synergism
DE3536939A1 (de) * 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
CA1340698C (en) * 1986-07-25 1999-08-10 Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo Preparation and uses of interferon-gamma
JP2632849B2 (ja) * 1986-07-25 1997-07-23 株式会社 林原生物化学研究所 γ―インターフェロンの製造方法
GB8619725D0 (en) * 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments

Also Published As

Publication number Publication date
DE68924316T2 (de) 1996-04-04
KR900003208A (ko) 1990-03-26
EP0353910B1 (en) 1995-09-20
KR100190555B1 (ko) 1999-06-01
AU3881889A (en) 1990-01-25
JP2969461B2 (ja) 1999-11-02
CA1340704C (en) 1999-08-10
DE68924316D1 (de) 1995-10-26
JPH02152998A (ja) 1990-06-12
EP0353910A3 (en) 1990-06-06
ATE128188T1 (de) 1995-10-15
EP0353910A2 (en) 1990-02-07
AU618382B2 (en) 1991-12-19

Similar Documents

Publication Publication Date Title
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
DE69023073D1 (de) Herstellung von Vorrichtungen mittels lithographischer Prozesse.
DE3763011D1 (de) Systeme zur verbesserung der durchdringungsfaehigkeit und deren zubereitung.
NO914115L (no) Fremgangsmaate for fremstilling av peroksidiske perfluorpolyetere
DK0791571T3 (da) Benzoylderivater
IT1232889B (it) Composizioni e procedimento per il trattamento ammorbidente di tessuti
ZW22687A1 (en) Treatment of diseases caused by viruses
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
FI895064A7 (fi) Syklosporiinia sisältäviä koostumuksia silmätulehdusten hoitoon
NO891894D0 (no) Fremgangsmaate for fremstilling av antikoagulerende peptidalkoholer.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
MC1930A1 (fr) Produit antiviral
FI902901A0 (fi) Dibenzol/1,5/dioxocin-5-one-derivat, deras anvaendning i laekemedel och foerfarande foer deras framstaellning.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
IT8922246A0 (it) Procedimento di preparazione di 3-ciano-3,5,5'-trimetil-1-cicloesanone
EP0295350A3 (en) Use of n-û2-(diethylamino)ethyl¨-2-methoxy-4-û(1-h 4,5-dihydro-2-imidazolyl)amino¨-5-chlorobenzamide as an anxiolytic and antipsychotic agent
TR24449A (tr) Tiyazinol tuerevleri hazirlanmalarina mahsus usul v ve fungusid olarak kullanimi
DE3786682D1 (de) Acth-fragmente enthaltende pharmazeutische zusammensetzungen zur behandlung von schockzustaenden sowie von respiratorischen und herz-kreislauf-insuffizienzen.
IT8821211A0 (it) Processo per la preparazione di perfluoro (2 bromoetilviniletere).
RO105809B1 (ro) PROCEDEU PENTRU PREPARAREA bis-N,N'-(DIMETILFORMAMIDO)
IT1217837B (it) Procedimento per la preparazione del "alfa /4(1,1 dimetiletil)fenil/piperidinbutanolo"
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
IT8721673A0 (it) Analoghi di 7 ossabiciclo (2.2.1) eptano.
DE3788424D1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 353910

Country of ref document: ES